Aspirin intolerance is particularly common in asthmatic complete, but suggest that ASA-sensitive asthma is most patients who additionally have chronic rhinitis andlor nasal likely to be related in some manner to the capacity of ASA to polyps. These individuals differ in several respects from inhibit cyclooxygenases, enhanced lipoxygenase metabopatients who experience urticaria and/or angioedema after lism perhaps playing a crucial role. Current research emaspirin administration, and differing mechanisms may be ploying ASA "desensitization" may help to elucidate these involved. Data regarding the latter are indirect and inenigmas.
dverse-even fatal-reactions to aspirin (ASA) in-
A gestion have been known to occur in "sensitive" individuals since the early 1900s. These reactions, occurring 20 minutes to three hours after ingestion,' usually present as primarily: 1) a respiratory pattern dominated by bronchospasm, rhinorrhea, conjunctivitis and/or flushing; 2) by an urticarialangioedema response; or 3) rarely as a combination of these patterns. While ASA sensitivity occurs among a few apparently healthy persons' and chronic rhinitis patient^,^ it is much more common among those with asthmaZ and/ or nasal polyps. Although occurring in childre11,~ the frequency of this pattern increases with age' and is typically of the mixed respiratory type.'.'.Asthmatic patients with nasal polyps and aspirin sensitivity commonly are referred to as triad asthmatics. However, provocation of nasal symptoms may be the sole manifestation of sensitivity in a subgroup of nonasthmatic subjects with rhinosinusitis and tendency towards polyps."mong asthmatic patients with a history of aspirin intolerance, oral ASA challenge has resulted in both an asthmatic and naso-ocular response in 66 percent of 50 subjects, purely an asthmatic response in 6 percent, purely a naso-ocular response in 6 percent, and no response in 16 percent.' Asthmatic responses also can be induced through ad~ninistering ASA by aerosol.' Spontaneous remission of ASA sensitivity has been documented in a few cases by repeated challenge with ASA after several years. ' Estimates of the prevalence of ASA sensitivity are enor~nously variable, ranging from 0.9 percent in normal subjectsZ to 78 percent in a selected population of severe asthmatic patients with nasal polyps.' Within this spectrum it has been reported in 1.4 percent of chronic rhinitis patients,' 14-22 percent of persons with nasal polypsJ and 3.8-28 percent of asthmatic patients in general.Z3 Part of this variability can be attributed to varying criteria for this diagnosis, such as history alone vs challenge testing, and the lack of standardization of challenge tests. The urticaria1 response, common in chronic urticaria patients, more likely has a different pathogenesis (perhaps occasionally IgE mediated) than does the respiratory reaction which is the subject of this discussion. Clinical features of ASA sensitivity1' are shown in Table 1 . Longstanding vasomotor rhinitis and severe intrinsic asthma often precede ASA s e n~i t i v i t y . '~~ Nasal polyposis and usually the asthma persist despite avoidance of aspirin." Although a familial clustering of asthma, rhinitis and ASA sensitivity has been seen,u there was discordance of ASA sensitivitv in the two monozygotic twin pairs r e p~r t e d , ' .~ as well as documented improvement in asthma after ASA in a sibling of an ASA-sensitive proband in another kindred.u In a study of a small number of patients, HLA AUB8 was preponderant, but this haplotype may be increased in asthma per se.13 The role of mast cell or basophil-derived mediators and complement activation has received attention with equivocal results. Although increases in venous whole blood and plasma histamine have been reported in ASA-induced asthma, other reports indicateLh no change from baseline in arterial and venous plasma or urinary histamine (H) or neutrophil chemotactic activity during reactions. In addition, in some asthmatic patients an increase in plasma H was not accompanied by a clinical reaction. Finally, ability to assess plasma H is plagued by the problem of rapid metabolism in oioo and of unreliability of various assay techniques. Other studies of the role of mediator release using cromolyn as a potential inhibitor of the clinical response have also given conflicting results: in some instances there was a delay in the fall of FEV,, while in others no effect on the reaction onset or magnitude was observed. In a study in which the antihistamine clemastine appeared to block the ASA reaction in some patients, the mere five-day interval between the successive ASA challenges did not rule out partial desensitization by the previous reaction. The recently reported protective eflect of ketotifen might be due either to this drug's mast cell-stabilizing effect or to its antihistamine properties."
Although ingestion of ASA in sensitive asthmatic patients has been reported to produce a fall in plasma complement, in some patients this occurs after salicylate ingestion in the absence of an asthmatic response. In addition, ASA and salicylate produced similar declines in serum complement and C1 esterase inhibitor in oitrolhand it1 oioo in norrnal subjects and in nonsensitive asthmatic patient^.'^ Confirming our own experience with five triad asthlnatic patients, anaphylatoxin inactivator (serum carboxypeptidase N) has been reported to be present in normal amounts in ASA-intolerant persons. Finally, others have observed no change in arterial or venous plasma CH,, C4, or C4d chemotactic activity during positive ASA chall e n g e~.~" A possible intermediary role for a cholinergic mechanism in ASA-induced asthma has been considered, but methacholine bronchial challenge was still positive in two patients "desensitized" to aspirin (although it was not stated whether a change in threshold occurred). We have observed no change in threshold reactivity to inhaled methacholine in three patients following ASA desensitization. Possible involvement of the contact system requires further investigation.
It seems most likely that ASA-induced asthma in some way is secondary to this drug's etfects on arachidonic acid nletabolism. As is well known, this cell membrane fatty acid can be metabolized along two pathways (Fig 1): (1) via cyclooxygenase to unstable endoperoxides which are subsequently converted in various proportions to prostaglandins (PGs), thrornboxanes (TX), and prostacyclin, depending on tissue type and stimulus, and (2) via lipoxygenase peroxidation to hydroperoxyeicosatetraenoic acids (HPETEs) which are precursors in the formation of hydroxyeicosatetraenoic acids (HETEs) and leukotrienes (LTs). The latter include LTC,, LTD, and LTE,, which comprise the classic slow-reacting substance of anaphylaxis (SRS-A) that is released during anaphylaxis and by other stimuli. Both the physiologic and pharmacologic effects of the cyclooxygenase and lipoxygenase derivatives are complex, varying with species, stimulus, cell source, and target cells among other factors. Regarding PGs in man, those of the F, A, B, and D, series and TXB, are bronchoconstrictors, while E series PGs and PGI, bron~hodilate.".~' The bronchoconstrictor eflect of PGF, appears to be mediated through cholinergic ~nechanisms.~ Not only are cyclooxygenase products released during anaphy l a x i~,~ but specifically the PGF, metabolite has been reported to be released in allergen-induced asthma. In addition, the PGs thenlselves affect mediator release; for example, PGE blocks antigen-induced histamine and SRS-A release from sensitized human lung and histamine release from b a~o p h i l s ,~~. '~ while PGF, enhances antigen induced mediator release." These effects probably are mediated through altered intracellular cyclic nucleotide levels.,' ASA and other cyclooxygenase inhibitors enhance antigen-induced release of SHS-A from lung and of histamine from lung and ba~ophils.".~ Some properties of the lipoxygenase metabolites in- times tlie potency of histamine oil a molar basis.'" 111 addition, these lipoxygenase products Iiave the potential to produce impaired mucociliary cleara~ice,'~ iiicreased mucus productio~i" aalid ~liucosal edenidi~ifil-tration. This occurs from shunting of arachidonic acid metabolism illto the 5-lipoxygenase pathway. In addition, t h e r e is evidencc that 5 -H P E T E , und 5-HETE enhance histamine release.& Other evidence suggesting that ASA sensitivity !nay be secondary to the capacity of ASA to block PC; synthesis is as follows: 1) there is a 60 to 100 percent incidence of crosssensitivity to aspirin by various structurally dissiniilar cyclooxygenase inhibiting nonsteroidal antiinf1an1-matory agents (NSAI),'5,J1 while sodiurii salicylate, a structurally siniilar agent with little capacity to inhibit PG synthesis, is usually well tolerated;" 2) desensitization to ASA produces desensitization to other NSAl and vice versa;.'") the potency of PG synthesis i~ilii-bition it1 oitro correlates with its i t ] oiuo potency in producing bronchospasni in sensitive asthniatics;." 4) in the rare instances in which ASA ingestion has been reported to improve asthma, other NSAl also had beneficial effects, while neither sodiunl salicylate nor salicyla~nide had a significant etfect:+' A possible weakness in this aspect of the hypothesis is the alleged cross-sensitivity of a few aspirin-sensitive patients to tartrazine,'." as well as a reported but less frequent cross-reactivity to Na benzoate' and aceta~ninophen, none of which is know~i to inhibit PC; s y~i t h e s i s .~ However, neither tartrazine nor Na benzoate cross re-.e other lipox!gel~a\t-1)roducts whicli are lrot b o d i~c c t l~ activity was denio~istrable in dou1)le-blind challe~iges by other i~ivestigators."
Civen thc potential of both cyclooxygcnase and lipoxyge~iase products to niediate an astli~natic reaction, there are several possible ways to explain ASA sensitivity within the fra~riework of the PC; i~iliibition hypothesis including: a) a change in the relative ratio of bronchoconstricti~ig to broncliodilating and niediator releasing/inhibiting PGs; b) increased se~isitivity to the bronchoconstricti~ig etfects of PCs; and c) a shift to the lipoxyge~iase pathway. 'The first postulate is 11ot borne out cxperi~nentally since botli baseline and post-ASA or piroxica~ii decreases in plasnia or scruni (111ostly platelet derived) PGE, PGF,,, and 'I'XB, were the sanie in asth~na reactors as no~ireacto~.s, " ir, tliere was no evidence of a sliift toward a less favorable ratio of bro~~choconstricti~ig to bronchodilatiiig PGs and '~X S .
' I Also, both PGE, and PGF, were tound to be elevated in a nasal polyp honioge~~ate of a11 ASA-intolerant asthniatic:" Howevel; the as yet unco~ifirnied fiiidi~ig of greater i~ihibitio~i by ASA of aracliido~~ic acid stin~u-lated production of WE,-like substa~~ces fro111 nasal polyp ho~nogenate or intact nasal polyps fioni ASA sensitive co~iipared to onse sensitive polypecton~y patielits suggests that there liiay be tissue-specific (or targetorgan specific) ditterences in sensitivit), to ASA." Sensitivity to PC;s theniselves appears the sanie in ASA-sensitive asthniatic patients as nonreactors since the fLrnier are: 1) not Inore se~isitive to bronclioconstrictive PC;s and may cwen have rtiot.c bronchodilatio~i than other asthn~atic patients to tlic same dose of PC;E2," and 2) they have tlie s a n e increase in lynipliocyte CAMP and beta-adreriergic receptor uu~iiber and function after PGE.39 Thus, it seems attractive to postulate that the shift to the lipoxygenase pathway is playing some role, which remains to be defined, in ASA-sensitive asthma. However, arguing against this hypothesis was the failure of oral benoxaprofen to raise the threshold or delay the onset of a clinical reaction in ASA-sensitive patients4' in spite of in uitro inhibition of SRS release. Thus, the lipoxygenase shift hypothesis is attractive, but as yet the release of SRS-A in blood or target issues during ASA-induced asthma has not been demonstrated.
ASA DESENSITIZATION
The possibility that patients could be desensitized to aspirin was suggested by the serendipitous finding of a 72-hour period of refractoriness to further aspirininduced symptoms after the respiratory reaction to an initial dose of a~p i r i n .~' This led to systematic desensitization of patients by the oral route,*' or by inhalat i~n .~ For example, Pleskow et al3\dministered serially increasing oral doses of aspirin (3, 30, 60, 100, 150, 300 mg) given at one-to three-hour intervals until at least a 25 percent fall in FEV, was elicited. Even with gradually increasing doses, the elicited reactions may include very severe asthma, rhinitis, and conjunctivitis requiring very close monitoring in an intensive care unit or its equivalent. Following treatment of the reaction with isoetharine and return of FEV, to near baseline (usually within two to 24 hours), aspirin was readministered in a dose equal to the last dose given just prior to the reaction and was incrementally increased until 650 mg of aspirin was tolerated without symptoms or a significant decrease in FEV,. Such patients were defined as being "desen~itized."~~ Doses and dose intervals were individualized if a reaction reappeared. The number of reactions required before desensitization was achieved correlated inversely with the cumulative dose required to provoke the initial reaction and was as high as six reactions, ie, seven of 11 patients reacting to a cumulative ASA dose of 150 mg or less experienced more than one reaction before becoming desensitized, three of l 2 reacting at 280-450 mg had more than one reaction, and none of seven reacting at 500 mg or more experienced this type of problem. Two of our patients experienced five reactions before becoming desensitized. Following desensitization, patients are nonreactive to ASA for an average of two to four days with a range of 1-30 The desensitized state usually can be maintained virtually indefinitely by daily oral ASA, but one case has been reported of relapse after six months of successful aspirin desensitization (while receiving propranolol)." In our own experience, as with that ofpublished series, patients usually tolerate substantial, therapeutic doses of ASA after "desensitization." Cross desensitization to other NSA16 (eg, indomethacin) occurs after ASA desensitization, and, conversely, desensitization to ASA develops after a reaction to other NSAI.'.' An initial report suggested overall clinical improvement in asthma ofdesensitized patients who continued to take daily aspirin, but this remains to be confirmed by further controlled studiesi5 (Table 2) . One difficulty has been that these reports often have been based on subjective criteria or semiquantitative parameters not easily subject to statistical analysis. Even in the more successful trials, a significant portion of patients had worsening of symptoms which often required discontinuation of ASA. Rhinosinusitis symptoms improved more consistently than FEV,,"i5 an observation which is in accord with our experience. Responses did not correlate with the maintenance dose of ASA used nor other variables studied.-15 Finally, daily ASA had no effect on asthma severity in ten children with moderately severe, non-aspirin sensitive a~t h m a .~'
To date, the mechanism of desensitization has not been elucidated. Some possibilities include: 1) depletion of mediators by ASA-induced reactions; 2) saturation of sites responsive to aspirin thereby preventing further release of mediators by aspirin; 3) tachyphylaxis to mediators; 4) increased clearance andlor degradation of mediators (eg, the induction of histaminase); 5) release of mediators during an initial reaction causing feedback inhibition of further mediator release; or 6) there may be a decrease in nonspecific airway irritability. Our preliminary studies have shown essentially no change in threshold for positive codeine (a nonspecific histamine liberator) and aeroallergen immediate skin test reactions after ASA desensitization. Likewise, responses to bronchial challenge with aeroallergens are not significantly altered. These observations argue against mediator depletion being responsible for ASA desensitization. A similar deduction might be made from the reported ability of ketotifen, an inhibitor of mast cell degranulation, to block ASA-induced reaction in a triad asthmatic but yet not prevent desensitization.'' Although conclusions from this strictly anecdotal and not quantified report are confounded by the probable multiplicity of mechanisms of actions of ketotifen (eg, H1 antihistamine effect), it suggests the possibility of a way of desensitizing without first provoking a reaction. In our patients, sensitivity to mediator and to cholinergic stimuli appeared to remain intact since the response thresholds for bronchial histamine and methacholine challenges were unchanged after ASA desensitization. Perhaps research employing ASA desensitization may not only shed light on this common clinical enigma, but possibly this information also may provide clues as to why these patients often have a severe, refractory and idiopathic type ofasthma even when assiduously avoiding ASA and related drugs.
NOTE: The more com lete bibliography used in preparing this review may be obtainecffrom the authors.
